Patent intelligence · US
US 8901173
Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
Patent details — US 8901173
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 2, 2014
- Expiration
- Nov 27, 2034
- Applicant
- Jazz Pharmaceuticals, Inc.
- Claims
- 33
- CPC classes
- A61K, A61K31/19, A61K31/554, A61K9/0053
Quick answer
US 8901173 (Gamma-hydroxybutyrate compositions and their use for the treatment of disorders) is held by Jazz Pharmaceuticals, Inc.. Status: granted. Granted Dec 2, 2014. Expires Nov 27, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Jazz Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 33
- CPC classes
- A61K, A61K31/19, A61K31/554, A61K9/0053, A61K9/08, A61P
More from Jazz Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12427160
Use of cannabinoids in the treatment of epilepsy
granted -
US 12403136
Cannabinoid derivatives as pharmaceutically active compounds and methods of preparation thereof
granted -
US 12396963
Cannabidiol-type cannabinoid compound
granted -
US 12383512
Cannabidiol-type cannabinoid compound
granted -
US 12383567
Use of cannabinoids in the treatment of epilepsy
granted -
US 12364670
Cannabidiol-type cannabinoid compound
granted -
US 12357586
Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
granted -
US 12350253
Use of cannabinoids in the treatment of dyskinesia associated with parkinson's disease
granted
Frequently asked questions
What is US patent 8901173?
US 8901173 (Gamma-hydroxybutyrate compositions and their use for the treatment of disorders) is held by Jazz Pharmaceuticals, Inc.. Status: granted. Granted Dec 2, 2014. Expires Nov 27, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8901173?
Jazz Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 89 pharmaceutical patents for this assignee.
When does US 8901173 expire?
Our index shows an expiration date of Nov 27, 2034 (8 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.